<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29967">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01716117</url>
  </required_header>
  <id_info>
    <org_study_id>SP-04</org_study_id>
    <nct_id>NCT01716117</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms</brief_title>
  <acronym>SCENT</acronym>
  <official_title>The Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms (SCENT Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stryker Neurovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stryker Neurovascular</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical research study is designed to determine safety and effectiveness of the
      Surpass Flow Diverter (Surpass System), an investigational device developed to treat wide
      neck, large or giant intracranial aneurysms.  An intracranial aneurysm is a bulge in the
      wall of a blood vessel in the brain.  The bulge is caused by a weakening of the vessel wall.
      If left untreated, the bulge may continue to grow larger and ultimately the vessel may break
      open (rupture), resulting in serious bleeding into our around the brain.  The information
      collected from this study will be used to evaluate how well patients do when treated with
      the Surpass System both immediately after treatment of an aneurysm and over a long period of
      time (5 years).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to determine safety and effectiveness of the Surpass Flow
      Diverter (Surpass System) in the endovascular treatment of large or giant wide-necked
      intracranial aneurysms in the internal carotid artery up to the terminus.  The Surpass Flow
      Diverter is an intracranial implant designed to be placed in a parent artery so as to divert
      blood flow away from an aneurysm. Use of the Surpass System may be associated with a
      decrease in neurological death or ipsilateral stroke in patients with large or giant
      wide-neck aneurysms. In a given patient, the Surpass System will be deemed effective if
      treatment results in complete occlusion of their aneurysm without clinically significant
      stenosis of the parent artery at one year.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Primary Effectiveness</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Percent of subjects with 100% occlusion of the aneurysm without clinically significant stenosis (defined as less than or equal to 50% stenosis) of the parent artery based on core lab evaluation of the 12 month follow up angiogram and without any subsequent treatment of the target aneurysm at the 12 month follow up visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percent of subjects experiencing neurologic death or major ipsilateral stroke through 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Safety</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Percent of subjects experiencing one or more serious adverse events through 12 months post-index procedure within the following two categories (as adjudicated by the Clinical Events Committee) - (1) proportion of subjects with new or worsening major ipsilateral stroke, and 2) proportion of subjects experiencing acute or subacute (&lt; 6 weeks) thrombosis of the Surpass Implant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Brain Aneurysm</condition>
  <arm_group>
    <arm_group_label>Surpass Flow Diverter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The objective of this study is to determine safety and effectiveness of the Surpass Flow Diverter (Surpass System) in the endovascular treatment of large or giant wide-necked intracranial aneurysms in internal carotid artery up to the terminus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Surpass Flow Diverter</intervention_name>
    <description>Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open.  Each device is delivered through a small catheter (a long, flexible tube).  The catheter containing the device is inserted and advanced into a vessel in the brain.  The device is then placed in the brain vessel by releasing it from the catheter.  Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm.  This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.</description>
    <arm_group_label>Surpass Flow Diverter</arm_group_label>
    <other_name>Flow diverter</other_name>
    <other_name>Endovascular aneurysm treatment</other_name>
    <other_name>Surpass NeuroEndoGraft System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject understands the nature of the procedure and provides written informed consent

          -  Subject is willing to return to the investigational site for all scheduled follow-up
             visits

          -  Subject is 19 to 80 years of age

          -  Subject has a single targeted intracranial aneurysm

        Exclusion Criteria:

          -  Pregnancy

          -  Enrollment in another trial

          -  Allergy or contraindication to aspirin, Clopidogrel/Plavix, heparin, local or general
             anesthesia

          -  History of life threatening allergy to contrast dye

          -  Major surgery within previous 30 days or planned in the next 120 days after
             enrollment date

          -  Severe neurological deficit that renders the subject incapable of living
             independently

          -  Dementia or psychiatric problem that prevents the patient from completing required
             follow up

          -  Co-morbid conditions that may limit survival to less than one year

          -  Subject with anatomy not appropriate for endovascular treatment due to severe
             intracranial vessel tortuosity or stenosis, or a history of intracranial vasospasm
             not responsive to medical therapy

          -  Subject with an intracranial mass, or is undergoing radiation therapy for carcinoma
             or sarcoma of the head or neck region

          -  Subject has a history of bleeding diathesis or coagulopathy, international normalized
             ratio (INR) greater than 1.5, or will refuse blood transfusions

          -  Subject has a serum creatinine level greater than 2.5mg/dL (within 7 days of
             procedure) which the investigator determines restricts the use of contrast agents

          -  Stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral
             artery) or intracranial artery within 30 days prior to treatment date

          -  Subject has a previous intracranial implant associated with the symptomatic
             distribution within the past 12 weeks prior to treatment date

          -  Subject has other known serious concurrent medical conditions such as heart disease,
             pulmonary disease or uncontrolled diabetes

          -  Subject had a subarachnoid hemorrhage within 30 days prior to the enrollment date

          -  Subject with resistance to Clopidogrel

          -  Subject has a non-treated arteriovenous malformation (AVM) in the territory of the
             target aneurysm
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo A Hanel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic, Jacksonville, Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Doug Follett, DVM, DACVA</last_name>
    <phone>510-413-2207</phone>
    <email>doug.follett@stryker.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rita Paparazzo</last_name>
    <phone>508-351-8632</phone>
    <phone_ext>225</phone_ext>
    <email>rpaparazzo@boston-biomedical.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Barrows Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolle Wilson</last_name>
      <email>Nicolle.Wilson@neurosurgery.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Spiros Blackburn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian L Hoh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessie Sperrazza</last_name>
      <email>sperrazza.jessie@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Ricardo Hanel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rabih G Tawk, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David A Miller, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Orendorff-Alegre</last_name>
      <email>SarahO@baptisthealth.net</email>
    </contact>
    <investigator>
      <last_name>Italo Linfante, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guilherme Dabus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haydy Rojas</last_name>
      <email>hrojas@tgh.org</email>
    </contact>
    <investigator>
      <last_name>Peter T Kan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zinovy M Katz, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christy M Anton</last_name>
      <email>Christy_Anton@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Demetrius K Lopes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Chen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roham Moftakhar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Michniewicz, RN</last_name>
      <email>bwawrys1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Alexander L Coon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geoffrey P Colby, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Li-mei Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Minnesota</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Connelly, CCRP</last_name>
      <email>connelly.beth@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Guiseppe Lanzino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Harry J Cloft, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David F Kallmes, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Cox, RN</last_name>
      <email>vc94@mail.cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Philip M Meyers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel H Sahlein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sean D Lavine, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Agugliaro, MBA</last_name>
      <email>Giuseppe.Agugliaro@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Tibor Becske, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maksim Shapiro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Howard A Riina, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter K Nelson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Jamieson</last_name>
      <email>rosssar@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Stanley Barnwell, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aclan Dogan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Tremarki</last_name>
      <email>Pamela.Tremarki@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Pascal Jabbour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stavropoula Tjoumakaris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian T Parker</last_name>
      <email>parkerad@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Raymond D Turner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>M Imran Chaudry, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aquilla S Turk, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alejandro M Spiotta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chesney S Oravec</last_name>
      <email>chesney.s.oravec@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>J Mocco, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Froehler, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas - Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Dutton-Johnson, RN</last_name>
      <email>kim.dutton@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Babu Welch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>G Lee Pride, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Dubler</last_name>
      <email>lisa.dubler@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Philipp Taussky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Edwin A Stevens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC St Radboud</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inge ter Horst</last_name>
      <email>i.terhorst@crcn.umcn.nl</email>
    </contact>
    <investigator>
      <last_name>Joost de Vries, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hieronymus D Boogaarts, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 24, 2014</lastchanged_date>
  <firstreceived_date>October 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Large aneurysm</keyword>
  <keyword>Giant aneurysm</keyword>
  <keyword>Wide neck aneurysm</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Intracranial Aneurysm</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
